Alterity Therapeutics Limited Stock Today
| PRNAF Stock | USD 0 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Alterity Therapeutics is trading at 0.0036 as of the 29th of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.0036. Alterity Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Alterity Therapeutics Limited are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimers disease, Huntington disease, Parkinsons disease, and other neurological disorders in Australia. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. The company has 2.41 B outstanding shares. More on Alterity Therapeutics Limited
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Alterity Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Alterity Therapeutics Limited [PRNAF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Micro-Cap' category with a current market capitalization of 18.77 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alterity Therapeutics's market, we take the total number of its shares issued and multiply it by Alterity Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Alterity Therapeutics classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 2.41 B outstanding shares.
Alterity Therapeutics Limited has accumulated about 34.81 M in cash with (12.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Alterity Therapeutics Probability Of Bankruptcy
Ownership AllocationAlterity Therapeutics holds a total of 2.41 Billion outstanding shares. Alterity Therapeutics Limited shows 15.14 percent of its outstanding shares held by insiders and 0.33 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alterity Ownership Details
Alterity Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Alterity Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Alterity Therapeutics Corporate Management
| BBus CA | Company Sec | Profile | |
| Robert Cherny | Head Research | Profile | |
| Kathryn Andrews | Chief Officer | Profile | |
| BSc BSc | CoFounder Chairman | Profile | |
| Steven Targum | Chief Advisor | Profile | |
| David MD | Chief Officer | Profile | |
| Rudolph Tanzi | Chief Board | Profile |
Other Information on Investing in Alterity Pink Sheet
Alterity Therapeutics financial ratios help investors to determine whether Alterity Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterity with respect to the benefits of owning Alterity Therapeutics security.